Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
Search results
529 results
-
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
In development [GID-TA10667] Expected publication date: TBC
-
Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
In development [GID-TA10697] Expected publication date: TBC
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: 15 December 2021
-
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]
In development [GID-TAG430] Expected publication date: 03 March 2021
-
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]
In development [GID-TA10729] Expected publication date: TBC
-
GID-MT550 DyeVert for reducing contrast media in coronary and peripheral angiography (MT488)
In development [GID-MT550] Expected publication date: 04 October 2021
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
In development [GID-TA10701] Expected publication date: 20 July 2022
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 04 May 2022
-
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education
In development [GID-NG10113] Expected publication date: 19 January 2022
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: 21 April 2021
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 21 April 2021
-
Andexanet alfa for reversing anticoagulation [ID1101]
In development [GID-TA10440] Expected publication date: 14 April 2021
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: 26 May 2021
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: TBC
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]
In development [GID-TA10806] Expected publication date: TBC
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 09 March 2022
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
In development [GID-TA10708] Expected publication date: 22 December 2021
-
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
In development [GID-TA10527] Expected publication date: TBC
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]
In development [GID-TA10299] Expected publication date: TBC
-
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]
In development [GID-TA10562] Expected publication date: 03 March 2021
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Multiple sclerosis - sativex [ID387]
In development [GID-TAG368] Expected publication date: TBC
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC
-
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: TBC
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: TBC
-
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]
In development [GID-TA10626] Expected publication date: 21 July 2021
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: 20 October 2021
-
Adults with complex needs: social work interventions including assessment, care management and support
In development [GID-NG10145] Expected publication date: 27 April 2022
-
GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation
In development [GID-MT554] Expected publication date: 06 January 2022
-
Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (update of DG21) (provisional title)
In development [GID-DG10042] Expected publication date: 13 April 2022
-
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)
In development [GID-MT557] Expected publication date: 22 March 2022
-
Erenumab for preventing migraine [ID1188]
In development [GID-TA10302] Expected publication date: TBC
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 November 2021
-
MT507 Plus Sutures for preventing surgical site infection
In development [GID-MT558] Expected publication date: 09 November 2021